![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1722677
±¤À¯ÀüÇÐ(Optogenetics) ½ÃÀå º¸°í¼ : Á¶¸í ±â±â À¯Çü, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2025-2033³â)Optogenetics Market Report by Light Equipment Type (Light-emitting Diode, Laser), Application, End User, and Region 2025-2033 |
¼¼°è ±¤À¯ÀüÇÐ ½ÃÀå ±Ô¸ð´Â 2024³â 514¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2033³â¿¡´Â 1,779¾ï ´Þ·¯¿¡ ´ÞÇϰí, 2025-2033³â 14.06%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. ÀÌ ½ÃÀåÀº ÁÖ·Î ±¤À¯ÀüÇÐ ±â¼úÀÇ ´«ºÎ½Å ¹ßÀü, ½Å°æ ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ¿¬±¸°³¹ß Ȱµ¿¿¡ ´ëÇÑ °ø°ø ¹× ¹Î°£ Á¶Á÷ÀÇ ¸·´ëÇÑ ÅõÀÚ¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.
±¤À¯ÀüÇÐÀº À¯ÀüÇаú ±¤ÇÐ ±â¼úÀÇ °áÇÕÀ» Æ÷ÇÔÇÏ´Â °úÇÐÀû Á¢±Ù¹ýÀ» ¸»ÇÕ´Ï´Ù. ÁÖ·Î ½Å°æ¼¼Æ÷¿Í ´Ù¸¥ À¯ÇüÀÇ ¼¼Æ÷ÀÇ »ý¹°ÇÐÀû ±â´ÉÀ» ±¤¼¾¼·Î Á¦¾îÇÏ°í ¸ð´ÏÅ͸µÇÏ´Â µ¥ »ç¿ëµË´Ï´Ù. ÀÌ Á¤º¸´Â ¿îµ¿, ÇнÀ, ±â¾ï, ³»ºñ°ÔÀ̼Ç, ½ÅÁø´ë»ç, È£Èí, ¼¾¼ ó¸® µî °³ÀÎÀÇ Çൿ°ú »ý¸®¿¡ ´ëÇÑ ÅëÂû·ÂÀ» Á¦°øÇÕ´Ï´Ù. ±¤À¯ÀüÇÐÀº ¸¸¼ºÅëÁõ, °£Áú, ÆÄŲ½¼º´, ³úÁ¹Áß, ¾à¹°Áßµ¶, °¹ÚÀå¾Ö(OCD), »çȸÀû ±â´ÉÀå¾Ö, ºÒ¾È, ¿ì¿ïÁõ µî ´Ù¾çÇÑ Áúȯ°ú °ü·ÃµÈ ¼¼Æ÷ Ȱµ¿À» ¹àÇô³»¾î ÀÓ»óÀû ¹ß°ß¿¡ µµ¿òÀ» ÁÙ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿ëµµ ¶§¹®¿¡ ±¤À¯ÀüÇÐÀº ½Å°æ°úÇÐ ºÐ¾ß¿¡¼ Æø³Ð°Ô Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù.
´Ù¾çÇÑ °¨¿°, Áúº´, À¯ÀüÀû Áúȯ, ¼±Ãµ¼º ±âÇü, ³ú-½Å°æ-ô¼ö ¼Õ»óÀ¸·Î ÀÎÇÑ ½Å°æ Àå¾ÖÀÇ À¯º´·ü Áõ°¡´Â ÇöÀç ±¤À¯ÀüÇÐ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ¿Í ÇÔ²², ÀÓÇöõÆ®¿¡ ³»ÀåµÈ ±¤¼¶À¯ °áÇÕ LEDÀÇ µµÀÔÀº Á¦¾à ¾ø´Â ±¤Àü¼ÛÀ» °¡´ÉÇÏ°Ô ÇÏ¿© ¶Ç ´Ù¸¥ ÁÖ¿ä ¼ºÀå ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ½Å°æ ¿¬°á, ¹«¼± ¸¶ÀÌÅ©·ÎĨ, ¼¾¼, ¼¼Æ÷ Ç¥ÇöÇü µµ±¸, CT(ÄÄÇ»ÅÍ ´ÜÃþ ÃÔ¿µ), PET(¾çÀüÀÚ ´ÜÃþ ÃÔ¿µ), MRI(Àڱ⠰ø¸í ¿µ»ó) µî Àå±â¿Í Á¶Á÷À» Á¤È®ÇÏ°Ô Æò°¡ÇÏ¿© Àå¾Ö¸¦ ½Äº°Çϱâ À§ÇÑ ´Ù¾çÇÑ À̹Ì¡ µµ±¸ÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀÌ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¼¼Æ÷Àû, °ø°£Àû, ½Ã°£Àû Á¤È®µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ÀÇ·á Àü¹®°¡µéÀÌ ±¤À¯ÀüÇÐÀû Ä¡·á¹ý¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ±âŸ ¿äÀÎÀ¸·Î´Â ÀÇ·áºñ Áõ°¡, ½Å°æ°úÇÐ ºÐ¾ßÀÇ ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿, ½Å°æÁúȯ Ä¡·á¸¦ À§ÇÑ ½Å¾à Ãâ½Ã¸¦ Áö¿øÇϱâ À§ÇÑ ÁÖ¿ä ±â¾÷, Á¦¾àȸ»ç, Á¤ºÎ °£ÀÇ Àü·«Àû Á¦ÈÞ µî ´Ù¾çÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ ½ÃÀå Àü¸ÁÀ» ¹à°Ô Çϰí ÀÖ½À´Ï´Ù.
The global optogenetics market size reached USD 51.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 177.9 Billion by 2033, exhibiting a growth rate (CAGR) of 14.06% during 2025-2033. The market is primarily driven by the notable developments in optogenetics technology, rising incidence of neurological illnesses, growing need for precision medicine, and substantial investment by public and private organizations in research and development activities.
Optogenetics refers to a scientific approach that includes a combination of genetics and optics technologies. It is primarily used for controlling and monitoring the biological functions of neurons and other types of cells with light sensors. This information provides insights into individual behavior and physiology, including movement, learning, memory, navigation, metabolism, respiration, and sensor processing. Optogenetics aids in clinical discoveries by shedding light on the cellular activities associated with various diseases, such as chronic pain, epilepsy, Parkinson disease, stroke, drug addiction, obsessive compulsion disorder (OCD), social dysfunction, and anxiety and depression. On account of these applications, optogenetics finds extensive utilization in the field of neurosciences.
The increasing prevalence of neurological disorders due to various infections, ailments, genetic disorders, congenital abnormalities, and brain, nerve, and spinal cord injuries is one of the key factors currently driving the optogenetics market growth. In line with this, the introduction of fiber-coupled light-emitting diode (LED) for being incorporated into the implants to enable the untethered light delivery is acting as another major growth-inducing factor. Additionally, rapid technological advancements in neural connectivity, wireless microchip, sensors, cell phenotyping tools, and various imaging tools, like computed tomography (CT), position emission tomography (PET), and magnetic resonance imaging (MRI) to precisely evaluate organs and tissues for identifying disorders is propelling the market growth. The rising inclination of healthcare professionals toward optogenetic therapeutic methodologies on account of its cellular, spatial, and temporal precision is further contributing to the market growth. Other factors, including increasing healthcare expenditure, extensive research and development (R&D) activities in the field of neurosciences, and strategic collaborations between key players, pharmaceutical companies, and governments of various nations to implement favorable policies that support the launch of novel drugs for treating neurological diseases, are creating a positive outlook for the market.
The competitive landscape of the industry has also been examined along with the profiles of the key players being Addgene, Coherent Inc., Elliot Scientific Limited, GenSight Biologics S.A., HUBNER GmbH & Co KG, Judges Scientific plc, Laserglow Technologies, Noldus Information Technology, Regenxbio Inc., Shanghai Laser & Optics Century Co. Ltd, The Jackson Laboratory and Thorlabs Inc.